Your browser doesn't support javascript.
loading
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Bang, Yeonghak; Yoo, Changhoon; Lonardi, Sara; Kim, Hyung-Don; Vivaldi, Caterina; Rimini, Margherita; Frassineti, Giovanni Luca; Park, Sook Ryun; Rizzato, Mario Domenico; Ryu, Min-Hee; Salani, Francesca; Rapposelli, Ilario Giovanni; Ryoo, Baek-Yeol; Zagonel, Vittorina; Massa, Valentina; Valgiusti, Martina; Burgio, Valentina; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea.
Afiliação
  • Bang Y; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Yoo C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Lonardi S; Early Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Kim HD; Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Vivaldi C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Rimini M; Department of Translational Research and New Surgical and Medical Technologies, University of Pisa, Via Savi 6, 56126, Pisa, Italy.
  • Frassineti GL; Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, Via del Pozzo 71, Modena, Italy.
  • Park SR; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Rizzato MD; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Ryu MH; Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Salani F; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Rapposelli IG; Department of Translational Research and New Surgical and Medical Technologies, University of Pisa, Via Savi 6, 56126, Pisa, Italy.
  • Ryoo BY; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Zagonel V; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Massa V; Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Valgiusti M; Department of Translational Research and New Surgical and Medical Technologies, University of Pisa, Via Savi 6, 56126, Pisa, Italy.
  • Burgio V; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Scartozzi M; Department of Medical Oncology, San Rafaele Scientific Institute IRCCS, Milan, Italy.
  • Cascinu S; Department of Medical Oncology, University Hospital of Cagliari, Cagliari, Italy.
  • Casadei-Gardini A; Department of Medical Oncology, San Rafaele Scientific Institute IRCCS, Milan, Italy.
Target Oncol ; 16(3): 411-412, 2021 May.
Article em En | MEDLINE | ID: mdl-33738697
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article